Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature.
about
TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunityFamilial Mediterranean fever: current perspectivesEULAR recommendations for the management of familial Mediterranean feverTreating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesBeyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescenceAssessment of neutrophil to lymphocyte ratio and mean platelet volume in pediatric familial Mediterranean fever patients.Interleukin-1 receptor antagonist expression is inversely associated with outcomes of hepatitis B-related acute-on-chronic liver failure.Systemic AA amyloidosis: epidemiology, diagnosis, and management.Genetic loss of murine pyrin, the Familial Mediterranean Fever protein, increases interleukin-1β levelsTolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesAn expanding role for interleukin-1 blockade from gout to cancer.Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatmentEfficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean feverEfficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Biological treatments: new weapons in the management of monogenic autoinflammatory disordersDivergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Familial Mediterranean fever: An updated review.Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.Treating inflammation by blocking interleukin-1 in humans.A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever.Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for ManagementImmunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.IL-1β biological treatment of familial Mediterranean fever.Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics.Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.FMF50: a score for assessing outcome in familial Mediterranean fever.Monogenic autoinflammatory diseases.Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever.The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.The myths we believed in familial Mediterranean fever: what have we learned in the past years?Protective and detrimental roles of inflammasomes in disease.Regulating against the dysregulation: new treatment options in autoinflammation.Biologic therapy in familial Mediterranean fever.A Comprehensive Overview of the Hereditary Periodic Fever Syndromes.Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens.Canakinumab for the treatment of familial Mediterranean fever.
P2860
Q24338801-26F135B3-6033-4E75-85BF-129F052A1090Q26751292-3B1AAFD5-7626-49D1-908A-02835DBBDC60Q26775286-C0AF5693-C169-4CE8-8B07-564315F10861Q26799747-08AA3E58-F674-4D22-AC98-1A97FE219FBAQ27011650-3C0D86B6-AC9B-401B-B397-6FABEA8189FBQ33560996-691A7885-88D9-455D-A700-433EB343634AQ33744626-2E74108E-220C-45BB-B74C-C449092F66BBQ34446219-A80C63D8-DEB1-42C4-A472-F46A048D6F23Q34506303-C7E4021A-143F-4CAD-B66F-ECC7B91A676FQ35122583-44222574-52E8-4E98-95BF-2FE82A8B62A0Q35133812-C810C485-EDBF-4DB6-BEED-59189778B144Q35219001-7E3E5C1F-3441-4F54-919F-588676B13735Q35535362-143DA187-F1F5-4909-A8F3-89FCE16B364CQ36027314-1ED0688C-AA3B-4E5F-99CB-C0258CA6EEA1Q36798016-EB9E7228-553E-42E8-9523-BCE0D91C84B6Q36816872-3DC263E9-A015-412D-B095-1B1544366975Q37077564-553BE986-2773-456F-80BC-A511D69C34C4Q37259317-3A60533E-0745-46F0-BD39-4A9E0CBF2579Q37270409-67F1E33A-2371-463A-8899-3C7858D775C3Q37296449-61F12BEE-07E6-49A5-9524-BC8CA3CD5420Q37466515-AE077D59-4321-40CA-B741-4EF19D751F15Q37636664-3293E245-F014-4489-A1FF-32C0B2D3B144Q37708258-6DCEBDFE-FFC6-4594-A0C9-EB033F0249DCQ37716794-96E938DE-9F83-497A-9E9C-D13834DFB69FQ37979862-EBB3A157-F57F-414F-955F-CA984AA98EE7Q38004932-C11FB2B5-F9F6-4D4B-A69D-494B7DFEA5CEQ38074355-0EE32BA2-5C0A-405D-AC8E-834603EC32EAQ38122566-BFCE73CD-76D8-4B34-A12B-0729DDC8F45DQ38151758-2197E49A-B5FC-4F92-879C-D62DEA8C102CQ38191175-025DEC30-48E2-41E9-9E4D-82D9876DB649Q38211947-819202AE-8C6D-4D9F-B8F7-75A2BB5E6254Q38241480-3AB8AEAF-8950-4EFE-8031-5FC02367B60AQ38389302-7951EF40-A84A-4BCB-85EC-2FE5D1D568DAQ38400573-0C53924E-7F8E-4F57-B58A-D0CFF2F1827FQ38431249-2FB18B69-D64A-4E00-A5D3-A836C2B93FDBQ38522837-13507A45-93D6-45AD-BCE6-F37B1C41EE41Q38759360-185D1626-5223-4B12-92C9-8E211853CE56Q38805718-721A11F0-6D55-47B6-AF0B-F68EF1302368Q38843398-C45735B2-42E5-4CEA-9D49-E8BE2F79D454Q38865019-E188C645-4434-4DC2-BE1C-32E3ACC411F7
P2860
Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interleukin-1 targeting drugs ...... nd a review of the literature.
@en
Interleukin-1 targeting drugs ...... nd a review of the literature.
@nl
type
label
Interleukin-1 targeting drugs ...... nd a review of the literature.
@en
Interleukin-1 targeting drugs ...... nd a review of the literature.
@nl
prefLabel
Interleukin-1 targeting drugs ...... nd a review of the literature.
@en
Interleukin-1 targeting drugs ...... nd a review of the literature.
@nl
P2093
P1476
Interleukin-1 targeting drugs ...... nd a review of the literature.
@en
P2093
Frédérique Retornaz
Jean-François Alexandra
Pierre Quartier
Ulrich Meinzer
Véronique Hentgen
P304
P356
10.1016/J.SEMARTHRIT.2010.11.003
P577
2011-02-01T00:00:00Z